Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Stem Cells

Omacetaxine may have a role in chronic myeloid leukaemia eradication through downregulation of Mcl-1 and induction of apoptosis in stem/progenitor cells

Abstract

Chronic myeloid leukaemia (CML) is maintained by a rare population of tyrosine kinase inhibitor (TKI)-insensitive malignant stem cells. Our long-term aim is to find a BcrAbl-independent drug that can be combined with a TKI to improve overall disease response in chronic-phase CML. Omacetaxine mepesuccinate, a first in class cetaxine, has been evaluated by clinical trials in TKI-insensitive/resistant CML. Omacetaxine inhibits synthesis of anti-apoptotic proteins of the Bcl-2 family, including (myeloid cell leukaemia) Mcl-1, leading to cell death. Omacetaxine effectively induced apoptosis in primary CML stem cells (CD34+38lo) by downregulation of Mcl-1 protein. In contrast to our previous findings with TKIs, omacetaxine did not accumulate undivided cells in vitro. Furthermore, the functionality of surviving stem cells following omacetaxine exposure was significantly reduced in a dose-dependant manner, as determined by colony forming cell and the more stringent long-term culture initiating cell colony assays. This stem cell-directed activity was not limited to CML stem cells as both normal and non-CML CD34+ cells were sensitive to inhibition. Thus, although omacetaxine is not leukaemia stem cell specific, its ability to induce apoptosis of leukaemic stem cells distinguishes it from TKIs and creates the potential for a curative strategy for persistent disease.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7

Similar content being viewed by others

References

  1. Kantarjian HM, Talpaz M, Santini V, Murgo A, Cheson B, O'Brien SM . Homoharringtonine: history, current research, and future direction. Cancer 2001; 92: 1591–1605.

    Article  CAS  PubMed  Google Scholar 

  2. de Lavallade H, Khorashad JS, Davis HP, Milojkovic D, Kaeda JS, Goldman JM et al. Interferon-alpha or homoharringtonine as salvage treatment for chronic myeloid leukemia patients who acquire the T315I BCR-ABL mutation. Blood 2007; 110: 2779–2780.

    Article  CAS  PubMed  Google Scholar 

  3. Quintas-Cardama A, Cortes J . Homoharringtonine for the treatment of chronic myelogenous leukemia. Expert Opin Pharmacother 2008; 9: 1029–1037.

    Article  CAS  PubMed  Google Scholar 

  4. Chen Y, Hu Y, Michaels S, Segal D, Brown D, Li S . Inhibitory effects of omacetaxine on leukemic stem cells and BCR-ABL-induced chronic myeloid leukemia and acute lymphoblastic leukemia in mice. Leukemia 2009; 23: 1446–1454.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Quintas-Cardama A, Kantarjian H, Cortes J . Homoharringtonine, omacetaxine mepesuccinate, and chronic myeloid leukemia circa 2009. Cancer 2009; 115: 5382–5393.

    Article  CAS  PubMed  Google Scholar 

  6. Powell RG, Weisleder D, Smith Jr CR . Antitumor alkaloids for Cephalataxus harringtonia: structure and activity. J Pharm Sci 1972; 61: 1227–1230.

    Article  CAS  PubMed  Google Scholar 

  7. Gurel G, Blaha G, Moore PB, Steitz TA . U2504 determines the species specificity of the A-site cleft antibiotics: the structures of tiamulin, homoharringtonine, and bruceantin bound to the ribosome. J Mol Biol 2009; 389: 146–156.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Tang R, Faussat AM, Majdak P, Marzac C, Dubrulle S, Marjanovic Z et al. Semisynthetic homoharringtonine induces apoptosis via inhibition of protein synthesis and triggers rapid myeloid cell leukemia-1 down-regulation in myeloid leukemia cells. Mol Cancer Ther 2006; 5: 723–731.

    Article  CAS  PubMed  Google Scholar 

  9. Aichberger KJ, Mayerhofer M, Krauth MT, Skvara H, Florian S, Sonneck K et al. Identification of mcl-1 as a BCR/ABL-dependent target in chronic myeloid leukemia (CML): evidence for cooperative antileukemic effects of imatinib and mcl-1 antisense oligonucleotides. Blood 2005; 105: 3303–3311.

    Article  CAS  PubMed  Google Scholar 

  10. Akgul C . Mcl-1 is a potential therapeutic target in multiple types of cancer. Cell Mol Life Sci 2009; 66: 1326–1336.

    Article  CAS  PubMed  Google Scholar 

  11. Chu S, Xu H, Shah NP, Snyder DS, Forman SJ, Sawyers CL et al. Detection of BCR-ABL kinase mutations in CD34+ cells from chronic myelogenous leukemia patients in complete cytogenetic remission on imatinib mesylate treatment. Blood 2005; 105: 2093–2098.

    Article  CAS  PubMed  Google Scholar 

  12. Sharma SV, Gajowniczek P, Way IP, Lee DY, Jiang J, Yuza Y et al. A common signaling cascade may underlie ‘addiction’ to the Src, BCR-ABL, and EGF receptor oncogenes. Cancer Cell 2006; 10: 425–435.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Copland M, Hamilton A, Elrick LJ, Baird JW, Allan EK, Jordanides N et al. Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction. Blood 2006; 107: 4532–4539.

    Article  CAS  PubMed  Google Scholar 

  14. Graham SM, Jorgensen HG, Allan E, Pearson C, Alcorn MJ, Richmond L et al. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood 2002; 99: 319–325.

    Article  CAS  PubMed  Google Scholar 

  15. Copland M, Pellicano F, Richmond L, Allan EK, Hamilton A, Lee FY et al. BMS-214662 potently induces apoptosis of chronic myeloid leukemia stem and progenitor cells and synergizes with tyrosine kinase inhibitors. Blood 2008; 111: 2843–2853.

    Article  CAS  PubMed  Google Scholar 

  16. Jorgensen HG, Allan EK, Jordanides NE, Mountford JC, Holyoake TL . Nilotinib exerts equipotent antiproliferative effects to imatinib and does not induce apoptosis in CD34+ CML cells. Blood 2007; 109: 4016–4019.

    Article  CAS  PubMed  Google Scholar 

  17. Konig H, Holyoake TL, Bhatia R . Effective and selective inhibition of chronic myeloid leukemia primitive hematopoietic progenitors by the dual Src/Abl kinase inhibitor SKI-606. Blood 2008; 111: 2329–2338.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Kobayashi T, Ruan S, Clodi K, Kliche KO, Shiku H, Andreeff M et al. Overexpression of Bax gene sensitizes K562 erythroleukemia cells to apoptosis induced by selective chemotherapeutic agents. Oncogene 1998; 16: 1587–1591.

    Article  CAS  PubMed  Google Scholar 

  19. Legros L, Hayette S, Nicolini FE, Raynaud S, Chabane K, Magaud JP et al. BCR-ABL(T315I) transcript disappearance in an imatinib-resistant CML patient treated with homoharringtonine: a new therapeutic challenge? Leukemia 2007; 21: 2204–2206.

    Article  CAS  PubMed  Google Scholar 

  20. Quintas-Cardama A, Kantarjian H, Garcia-Manero G, O'Brien S, Faderl S, Estrov Z et al. Phase I/II study of subcutaneous homoharringtonine in patients with chronic myeloid leukemia who have failed prior therapy. Cancer 2007; 109: 248–255.

    Article  CAS  PubMed  Google Scholar 

  21. Stone RM, Donohue KA, Stock W, Hars V, Linker CA, Shea T et al. A phase II study of continuous infusion homoharringtonine and cytarabine in newly diagnosed patients with chronic myeloid leukemia: CALGB study 19804. Cancer Chemother Pharmacol 2009; 63: 859–864.

    Article  CAS  PubMed  Google Scholar 

  22. Tipping AJ, Mahon FX, Zafirides G, Lagarde V, Goldman JM, Melo JV . Drug responses of imatinib mesylate-resistant cells: synergism of imatinib with other chemotherapeutic drugs. Leukemia 2002; 16: 2349–2357.

    Article  CAS  PubMed  Google Scholar 

  23. Chen R, Gandhi V, Plunkett W . A sequential blockade strategy for the design of combination therapies to overcome oncogene addiction in chronic myelogenous leukemia. Cancer Res 2006; 66: 10959–10966.

    Article  CAS  PubMed  Google Scholar 

  24. Tipping AJ, Deininger MW, Goldman JM, Melo JV . Comparative gene expression profile of chronic myeloid leukemia cells innately resistant to imatinib mesylate. Exp Hematol 2003; 31: 1073–1080.

    Article  CAS  PubMed  Google Scholar 

  25. Kuroda J, Puthalakath H, Cragg MS, Kelly PN, Bouillet P, Huang DC et al. Bim and Bad mediate imatinib-induced killing of Bcr/Abl+ leukemic cells, and resistance due to their loss is overcome by a BH3 mimetic. Proc Natl Acad Sci USA 2006; 103: 14907–14912.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Zhang B, Strauss AC, Chu S, Li M, Ho Y, Shiang KD et al. Targeting of quiescent chronic myelogenous leukemia stem cells by histone deacetylase inhibitors in combination with imatinib mesylate. Cancer Cell 2010; 17: 427–442.

    PubMed  PubMed Central  Google Scholar 

  27. Bellodi C, Lidonnici MR, Hamilton A, Helgason GV, Soliera AR, Ronchetti M et al. Targeting autophagy potentiates tyrosine kinase inhibitor-induced cell death in Philadelphia chromosome-positive cells, including primary CML stem cells. J Clin Invest 2009; 119: 1109–1123.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Heaney NB, Pellicano F, Zhang B, Crawford L, Chu S, Kazmi SM et al. Bortezomib induces apoptosis in primitive chronic myeloid leukemia cells including LTC-IC and NOD/SCID repopulating cells. Blood 2010; 115: 2241–2250.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

HGJ was supported by William Thyne Centenary Fellowship, Dr Rhona Reid Charitable Trust, and Louis and Marion Ferrar Trust. We are grateful to Kara Melchizedek for her contribution to cell-line data through her summer vacation project sponsored by the McGuigan family and the Pathological Society.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to T L Holyoake.

Ethics declarations

Competing interests

The authors declare that E Allan, Dr Jørgensen and Prof Holyoake received research support from ChemGenex Pharmaceuticals; Dr A Craig, an employee of ChemGenex Pharmaceuticals, originated and participated in the concept discussion that led to the experimental work.

Additional information

Supplementary Information accompanies the paper on the Leukaemia website

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Cite this article

Allan, E., Holyoake, T., Craig, A. et al. Omacetaxine may have a role in chronic myeloid leukaemia eradication through downregulation of Mcl-1 and induction of apoptosis in stem/progenitor cells. Leukemia 25, 985–994 (2011). https://doi.org/10.1038/leu.2011.55

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/leu.2011.55

Keywords

This article is cited by

Search

Quick links